OTC Prilosec In "MUPS" Formulation Confirmed By AstraZeneca Exec
This article was originally published in The Tan Sheet
Executive Summary
AstraZeneca's proton pump inhibitor Prilosec (omeprazole) will switch to OTC status in the U.S. in the "multi-unit pellet system" (MUPS) dosage form, Exec VP-Gastrointestinal Franchise Martin Nicklasson, PhD, stated at a briefing for securities analysts in London Dec. 6.